Limited Competition for the Continuation of the Drug Induced Liver Injury Network (DILIN) Clinical Centers (U01)
The purpose of this Funding Opportunity Announcement is for a limited competition for clinical centers for the continuation of the Drug-induced Liver Injury Network (DILIN). The DILIN Clinical Centers are the components of the Network to identify, enroll and clinically characterize patients eligible for the DILIN. The companion RFA (RFA-DK-17-510) seeks to continue the Data Coordinating Center for DILIN
Drug-induced liver injury (DILI) is one of the more challenging forms of liver disease; both in diagnosis and management. Several hundred drugs, nutritional supplements and herbal medications have been implicated in causing liver injury. Their clinical presentation can be highly variable and mimic almost any form of liver disease. Over the last 14 years, the DILIN Network throughout its publications (http://www.dilin.org/publications/) have become the major source of information and progress in understanding and possibly decreasing the burden of drug-induced liver injury for clinicians, hepatologists, researchers, and the public at large in the US and Worldwide.
Funding Opportunity Details
November 5, 2017
December 5, 2017), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.